<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01425164</url>
  </required_header>
  <id_info>
    <org_study_id>IVA-ISCHEMIA</org_study_id>
    <nct_id>NCT01425164</nct_id>
  </id_info>
  <brief_title>Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol</brief_title>
  <official_title>Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In hemodialysed patients, coronary heart disease is the leading cause of mortality and
      morbidity. Most of the commonly used drug for ischemia are used in this patients, but few
      prospective data are available. Among anti-ischemic drugs betablocker provided evidence of
      beneficial effects on outcome and, in dialysis patients, carvedilol was successfully used
      also in heart failure. Ivabradine is the latest anti-ischemic drug that provided evidence of
      benefit in general population, but no study is available in dialysis patients. Aim of the
      present study is to compare in a randomized, double-blind, parallel group trial the effects
      of ivabradine compared with carvedilol on event-free survival at 18 months in a hemodialysed
      population of patients with established coronary heart disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>event-free survival</measure>
    <time_frame>18 months</time_frame>
    <description>primary outcome was event-free survival at 18 months. The following ischemia related events were considered: death, resuscitation from ventricular tachycardia/fibrillation, nonfatal myocardial infarction, hospitalization for unstable angina, aggravation of angina requiring known antianginal therapy, and need for revascularization.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Angina</condition>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>ivabradine tablets, 5 to 7.5 mg bis-in-die.</description>
    <arm_group_label>Ivabradine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>carvedilol tablets, 12.5 to 25 mg bis-in-die.</description>
    <arm_group_label>Carvedilol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  documented CAD evidenced by either coronary angiography (&gt;50% diameter stenosis of a
             major coronary artery) or a previously documented myocardial infarction

          -  transient ischemia evidenced by abnormalities during an exercise ECG (standard Bruce
             protocol), myocardial perfusion scintigraphy, or stress regional wall motion study
             done within 6 months of study entry

        Exclusion Criteria:

          -  unstable angina pectoris

          -  myocardial infarction or coronary revascularization within 3 months of study entry

          -  an ECG abnormality interfering with exercise ST-segment interpretation (eg, ST-segment
             depression &gt;0.5 mm, QRS duration &gt;0.1 second, R-wave amplitude &lt;8 mm,preexcitation,or
             atrial fibrillation)

          -  inability to undergo exercise testing

          -  uncontrolled hypertension

          -  other serious condition (medical, psychiatric, cognitive, or social)

          -  symptoms of sufficient severity (Canadian class II or higher) to require antianginal
             medications other than nitrates

          -  heart failure

          -  greater than first-degree atrio-ventricular block, asthma, or other contraindications
             to betablocker therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gennaro Cice, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gennaro Cice, MD</last_name>
    <phone>+390815666642</phone>
    <email>gennarocice@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chair of Cardiology Second University of Naples</name>
      <address>
        <city>Naples</city>
        <zip>80100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2011</study_first_submitted>
  <study_first_submitted_qc>August 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2011</study_first_posted>
  <last_update_submitted>June 27, 2012</last_update_submitted>
  <last_update_submitted_qc>June 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>Gennaro Cice</investigator_full_name>
    <investigator_title>Responsible Cardiology Unit â„… Cappella Cangiani</investigator_title>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>coronary heart disease</keyword>
  <keyword>angina</keyword>
  <keyword>betablocker</keyword>
  <keyword>carvedilol</keyword>
  <keyword>ivabradine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

